KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) Gross Margin (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Gross Margin for 7 consecutive years, with 97.66% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Margin rose 229.0% year-over-year to 97.66%, compared with a TTM value of 97.82% through Dec 2025, up 54.0%, and an annual FY2025 reading of 97.82%, up 54.0% over the prior year.
  • Gross Margin was 97.66% for Q4 2025 at Biocryst Pharmaceuticals, down from 98.63% in the prior quarter.
  • Across five years, Gross Margin topped out at 98.64% in Q1 2024 and bottomed at 95.37% in Q4 2024.
  • Average Gross Margin over 3 years is 97.75%, with a median of 98.29% recorded in 2025.
  • The sharpest move saw Gross Margin plummeted -325bps in 2024, then surged 229bps in 2025.
  • Year by year, Gross Margin stood at 98.62% in 2023, then dropped by -3bps to 95.37% in 2024, then increased by 2bps to 97.66% in 2025.
  • Business Quant data shows Gross Margin for BCRX at 97.66% in Q4 2025, 98.63% in Q3 2025, and 98.29% in Q2 2025.